D'Angelo, Sandra P http://orcid.org/0000-0002-3736-3783
Bhatia, Shailender http://orcid.org/0000-0002-3816-2238
Brohl, Andrew S
Hamid, Omid
Mehnert, Janice M
Terheyden, Patrick
Shih, Kent C
Brownell, Isaac http://orcid.org/0000-0002-0090-9914
Lebbé, Celeste
Lewis, Karl D
Linette, Gerald P
Milella, Michele
Georges, Sara
Shah, Parantu
Ellers-Lenz, Barbara
Bajars, Marcis
Güzel, Gülseren
Nghiem, Paul T
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
https://doi.org/10.1136/jitc-2021-003302
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
https://doi.org/10.1136/jitc-2019-000313
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
https://doi.org/10.1136/jitc-2020-000674
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
https://doi.org/10.1136/jitc-2022-004742
604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
https://doi.org/10.1136/jitc-2022-sitc2022.0604
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
https://doi.org/10.1136/jitc-2021-002646
Efficacy and immune-related adverse event associations in avelumab-treated patients
https://doi.org/10.1136/jitc-2020-001427
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Documents that mention this clinical trial
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
https://doi.org/10.1136/jitc-2021-003302
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
https://doi.org/10.1136/jitc-2019-000313
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
https://doi.org/10.1136/jitc-2022-004742
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
https://doi.org/10.1136/jitc-2020-000674
604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
https://doi.org/10.1136/jitc-2022-sitc2022.0604
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
https://doi.org/10.1136/jitc-2021-002646
Efficacy and immune-related adverse event associations in avelumab-treated patients
https://doi.org/10.1136/jitc-2020-001427
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Documents that mention this clinical trial
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
https://doi.org/10.1136/jitc-2020-000674
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
https://doi.org/10.1136/jitc-2022-004742
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Funding for this research was provided by:
Merck KGaA (N/A)
Pfizer (N/A)